Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Cash from Financing Activities (2023 - 2025)

Historic Cash from Financing Activities for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Q3 2025 value amounting to $348000.0.

  • Monte Rosa Therapeutics' Cash from Financing Activities rose 222000.0% to $348000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year decrease of 9891.87%. This contributed to the annual value of $98.9 million for FY2024, which is 25971.19% up from last year.
  • Latest data reveals that Monte Rosa Therapeutics reported Cash from Financing Activities of $348000.0 as of Q3 2025, which was up 222000.0% from $365000.0 recorded in Q2 2025.
  • In the past 5 years, Monte Rosa Therapeutics' Cash from Financing Activities registered a high of $98.0 million during Q2 2024, and its lowest value of $14000.0 during Q1 2025.
  • Its 3-year average for Cash from Financing Activities is $11.6 million, with a median of $365000.0 in 2025.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first surged by 806858.33% in 2024, then plummeted by 9962.76% in 2025.
  • Monte Rosa Therapeutics' Cash from Financing Activities (Quarter) stood at $25.2 million in 2023, then crashed by 97.58% to $608000.0 in 2024, then plummeted by 42.76% to $348000.0 in 2025.
  • Its Cash from Financing Activities stands at $348000.0 for Q3 2025, versus $365000.0 for Q2 2025 and $14000.0 for Q1 2025.